Edition:
United Kingdom

Biogen Inc (BIIB.OQ)

BIIB.OQ on NASDAQ Stock Exchange Global Select Market

319.48USD
20 Nov 2018
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$319.48
Open
$318.96
Day's High
$323.30
Day's Low
$313.42
Volume
436,584
Avg. Vol
545,989
52-wk High
$388.67
52-wk Low
$249.24

Latest Key Developments (Source: Significant Developments)

Eisai And Biogen Announce Additional Data From The Phase II Clinical Trial Of Ban2401
Thursday, 25 Oct 2018 

Oct 25 (Reuters) - Biogen Inc ::EISAI AND BIOGEN ANNOUNCE PRESENTATION OF ADDITIONAL DATA FROM THE PHASE II CLINICAL TRIAL OF BAN2401 IN EARLY ALZHEIMER’S DISEASE AT THE 2018 CLINICAL TRIALS ON ALZHEIMER’S DISEASE (CTAD) CONFERENCE.EISAI AND BIOGEN ANNOUNCE PRESENTATION OF ADDITIONAL DATA FROM THE PHASE II CLINICAL TRIAL OF BAN2401 IN EARLY ALZHEIMER’S DISEASE AT THE 2018 CLINICAL TRIALS ON ALZHEIMER’S DISEASE (CTAD) CONFERENCE.BIOGEN INC - BAN2401 DEMONSTRATED AN ACCEPTABLE TOLERABILITY PROFILE THROUGH 18 MONTHS OF STUDY DRUG ADMINISTRATION.BIOGEN INC - EISAI AND BIOGEN ARE CURRENTLY DISCUSSING NEXT STEPS FOR BAN2401 WITH REGULATORY AUTHORITIES.BIOGEN INC - AN OPEN-LABEL EXTENSION FOR PATIENTS PREVIOUSLY ENROLLED IN STUDY 201 IS BEING PLANNED, WITH ENROLLMENT EXPECTED TO BEGIN THIS YEAR.BIOGEN - HIGHEST TREATMENT DOSE SHOWED STATISTICALLY SIGNIFICANT SLOWING OF CLINICAL DECLINE ON ADCOMS OF 30 PERCENT VERSUS PLACEBO AT 18 MONTHS.BIOGEN - FROM CONVENTIONAL ANALYSIS, HIGHEST TREATMENT DOSE DEMONSTRATED STATISTICALLY SIGNIFICANT REDUCTION IN BRAIN AMYLOID AT 18 MONTHS (P<0.0001).BIOGEN INC - BAN2401 DEMONSTRATED AN ACCEPTABLE TOLERABILITY PROFILE THROUGH 18 MONTHS OF STUDY DRUG ADMINISTRATION.  Full Article

UCB Phase 2B Study Of DZP In SLE: Primary Endpoint Not Met
Tuesday, 23 Oct 2018 

Oct 23 (Reuters) - UCB SA ::TOPLINE RESULTS FROM A PHASE 2B STUDY OF DAPIROLIZUMAB PEGOL IN SLE.PRIMARY ENDPOINT OF THE STUDY WAS NOT MET.STUDY DID DEMONSTRATE CONSISTENT AND POTENTIALLY MEANINGFUL IMPROVEMENTS FOR THE MAJORITY OF CLINICAL ENDPOINTS IN PATIENTS TREATED WITH DZP COMPARED WITH PLACEBO.DZP WAS WELL TOLERATED AND DEMONSTRATED AN ACCEPTABLE SAFETY PROFILE..BIOMARKER DATA DEMONSTRATED EVIDENCE OF PROOF OF BIOLOGY..  Full Article

Biogen Canada And pCPA Reach Agreement On Access To Treatment For Spinal Muscular Atrophy
Wednesday, 3 Oct 2018 

Oct 3 (Reuters) - Biogen Inc ::BIOGEN CANADA AND PAN-CANADIAN PHARMACEUTICAL ALLIANCE (PCPA) REACH AGREEMENT ON ACCESS TO FIRST AND ONLY APPROVED TREATMENT FOR SPINAL MUSCULAR ATROPHY (SMA) IN CANADA.BIOGEN CANADA - PUBLIC DRUG PLANS WILL COVER TYPE 1 PATIENTS AND BIOGEN WILL COVER MOST URGENT TYPE 2 AND 3 PATIENTS UNDER AN URGENT ACCESS PROGRAM.BIOGEN CANADA - REACHED AGREEMENT WITH PAN-CANADIAN PHARMACEUTICAL ALLIANCE TO PROVIDE SMA TYPE 1 PATIENTS WITH ACCESS TO BIOGEN'S PRODUCT, SPINRAZA.  Full Article

Biogen Inc To Repurchase Up To $3.5 Bln Of Company's Common Stock
Friday, 3 Aug 2018 

Aug 3 (Reuters) - Biogen Inc ::BIOGEN INC - DIRECTORS AUTHORIZED A PROGRAM TO REPURCHASE UP TO $3.5 BILLION OF THE COMPANY’S COMMON STOCK.BIOGEN INC SAYS 2018 SHARE REPURCHASE PROGRAM DOES NOT HAVE AN EXPIRATION DATE - SEC FILING.BIOGEN INC - ALL SHARE REPURCHASES UNDER 2018 SHARE REPURCHASE PROGRAM WILL BE RETIRED.  Full Article

Biogen Reports Qtrly Non-GAAP Earnings Per Share Of $5.80
Tuesday, 24 Jul 2018 

July 24 (Reuters) - Biogen Inc ::BIOGEN Q2 2018 REVENUES INCREASE 9% TO $3.4 BILLION.QTRLY EARNINGS PER SHARE (EPS) ATTRIBUTABLE TO BIOGEN INC. $4.18.QTRLY NON-GAAP EARNINGS PER SHARE $5.80.Q2 EARNINGS PER SHARE VIEW $5.21, REVENUE VIEW $3.25 BILLION -- THOMSON REUTERS I/B/E/S.IN Q2 GAAP DILUTED EPS IMPACTED BY $2.84 RELATED TO COLLABORATION AGREEMENT WITH IONIS PHARMACEUTICALS, AMONG OTHERS.QTRLY TECFIDERA REVENUE $1,087 MILLION VERSUS $1,111 MILLION.ACQUIRES MUSCLE ENHANCEMENT PROGRAM FROM ALIVEGEN.QTRLY SPINRAZA REVENUE $423 MILLION VERSUS $203 MILLION.ACQUISITION FROM ALIVEGEN INCLUDES AN UPFRONT PAYMENT OF $27.5 MILLION.UPDATING ITS FULL YEAR 2018 FINANCIAL GUIDANCE.2018 REVENUE EXPECTED TO BE ABOUT $13.0 BILLION TO $13.2 BILLION.BIOGEN - AS PER DEAL, MAY PAY ALIVEGEN UP TO $535 MILLION IN ADDITIONAL POTENTIAL DEVELOPMENT, COMMERCIALIZATION MILESTONES ACROSS BOTH ASSETS & MULTIPLE INDICATIONS.2018 GAAP DILUTED EPS IS EXPECTED TO BE BETWEEN $21.80 AND $22.40.2018 NON-GAAP DILUTED EPS IS EXPECTED TO BE BETWEEN $24.90 AND $25.50.FY2018 EARNINGS PER SHARE VIEW $23.97, REVENUE VIEW $12.97 BILLION -- THOMSON REUTERS I/B/E/S.HAS ACQUIRED ALG-801 (PHASE 1A) AND ALG-802 (PRECLINICAL) FROM ALIVEGEN INC.  Full Article

Biogen Exercises Option To Increase Ownership In Samsung Bioepis
Thursday, 28 Jun 2018 

June 28 (Reuters) - Biogen Inc ::BIOGEN EXERCISES OPTION TO INCREASE OWNERSHIP IN SAMSUNG BIOEPIS.BIOGEN INC - WILL PAY SAMSUNG BIOLOGICS APPROXIMATELY $700 MILLION TO INCREASE ITS OWNERSHIP IN SAMSUNG BIOEPIS TO APPROXIMATELY 49.9%.BIOGEN INC - DEAL INCREASING BIOGEN'S OWNERSHIP IN SAMSUNG BIOEPIS FROM APPROXIMATELY 5.4% TO APPROXIMATELY 49.9%.  Full Article

Alkermes Says Receives $50 Million Payment From Biogen
Wednesday, 6 Jun 2018 

June 6 (Reuters) - Alkermes Plc ::ALKERMES RECEIVES $50 MILLION PAYMENT FROM BIOGEN FOLLOWING REVIEW OF PRELIMINARY GASTROINTESTINAL TOLERABILITY DATA FROM THE ONGOING BIIB098 CLINICAL DEVELOPMENT PROGRAM.ALKERMES PLC - ALKERMES EXPECTS TO SUBMIT A NEW DRUG APPLICATION (NDA) FOR BIIB098 TO U.S. FOOD AND DRUG ADMINISTRATION (FDA) IN Q4 OF 2018.ALKERMES PLC - ALL OF PAYMENT WILL BE RECORDED AS LICENSE REVENUE IN ALKERMES' FINANCIAL RESULTS FOR QUARTER ENDING JUNE 30, 2018.ALKERMES - MAY ALSO RECEIVE $150 MILLION MILESTONE PAYMENT FROM BIOGEN UPON FDA APPROVAL, ON OR BEFORE DEC. 31, 2021, OF NDA FOR BIIB098.  Full Article

Biogen Reports Quarterly Revenues Of $3.1 Billion
Tuesday, 24 Apr 2018 

April 24 (Reuters) - Biogen Inc ::BIOGEN REPORTS QUARTERLY REVENUES OF $3.1 BILLION.Q1 REVENUE $3.1 BILLION VERSUS I/B/E/S VIEW $3.16 BILLION.QTRLY NON-GAAP DILUTED EPS $6.05.QTRLY EARNINGS PER SHARE $5.54.QTRLY SPINRAZA REVENUE OF $364 MILLION VERSUS $47 MILLION REPORTED LAST YEAR.QTRLY PLEGRIDY REVENUE OF $100 MILLION VERSUS. $112 MILLION REPORTED LAST YEAR.QTRLY TYSABRI REVENUE OF $$462 MILLION VERSUS. $545 MILLION REPORTED LAST YEAR.QTRLY TECFIDERA REVENUE OF $987 MILLION VERSUS $958 MILLION REPORTED LAST YEAR.QTRLY AVONEX REVENUE OF $451 MILLION VERSUS $537 MILLION REPORTED LAST YEAR.Q1 EARNINGS PER SHARE VIEW $5.94 -- THOMSON REUTERS I/B/E/S.  Full Article

Biogen, Samsung Bioepis To Settle With AbbVie Over Humira Biosimilar
Thursday, 5 Apr 2018 

April 5 (Reuters) - Biogen Inc ::BIOGEN AND SAMSUNG BIOEPIS AGREE TO SETTLEMENT WITH ABBVIE ALLOWING COMMERCIALIZATION OF IMRALDI™ (ADALIMUMAB BIOSIMILAR) IN EUROPE.BIOGEN EXPECTS TO LAUNCH IMRALDI IN EUROPE ON OCTOBER 16, 2018.PRECISE TERMS OF AGREEMENT WITH ABBVIE ARE CONFIDENTIAL.UNDER TERMS OF AGREEMENT, ABBVIE WILL GRANT PATENT LICENSES FOR USE AND SALE OF IMRALDI IN EUROPE.COUNTRY BASIS.UNDER TERMS OF AGREEMENT, BIOGEN AND SAMSUNG BIOEPIS WILL MAKE ROYALTY PAYMENTS TO ABBVIE.COMPANIES HAVE AGREED TO DISMISS ALL PENDING PATENT LITIGATION.  Full Article

Biogen Inc Reports Qtrly Loss Per Share Of $1.40
Thursday, 25 Jan 2018 

Jan 25 (Reuters) - Biogen Inc ::BIOGEN REPORTS RECORD REVENUES FOR BOTH THE FULL YEAR AND FOURTH QUARTER OF 2017, $12.3 BILLION AND $3.3 BILLION, RESPECTIVELY.2018 FULL YEAR REVENUE GUIDANCE OF $12.7 TO $13.0 BILLION.2017 GAAP EPS DECREASED 30%, INCLUDING A $1.2 BILLION CHARGE DUE TO U.S. TAX REFORM.QTRLY ‍NON-GAAP DILUTED EPS $5.26​.QTRLY LOSS PER SHARE $1.40.QTRLY PLEGRIDY REVENUE OF $125​ MILLION VERSUS. $125 MILLION.QTRLY TYSABRI REVENUE OF $463​ MILLION VERSUS. $474 MILLION.GAAP DILUTED EPS IS EXPECTED TO BE BETWEEN $22.20 AND $23.20 FOR 2018.QTRLY TECFIDERA REVENUE OF $1,076 MILLION VERSUS. $1,002 MILLION.NON-GAAP DILUTED EPS IS EXPECTED TO BE BETWEEN $24.20 AND $25.20 FOR 2018.QTRLY AVONEX REVENUE OF $520 MILLION VERSUS. $564 MILLION.FY2018 EARNINGS PER SHARE VIEW $24.16, REVENUE VIEW $12.68 BILLION -- THOMSON REUTERS I/B/E/S.Q4 EARNINGS PER SHARE VIEW $5.45, REVENUE VIEW $3.08 BILLION -- THOMSON REUTERS I/B/E/S.QTRLY TOTAL REVENUES $3,307 MILLION VERSUS $2,872 MILLION LAST YEAR.‍IN Q4 CO BOOKED A GAAP & NON-GAAP TAX CHARGE OF $42 MILLION & $50 MILLION, RESPECTIVELY, RELATED TO IMPAIRMENT OF ZINBRYTA RELATED TAX ASSETS​.  Full Article

Photo

AbbVie sees hit to Humira sales from European competition

U.S. drugmaker AbbVie Inc on Friday lowered its forecast for overseas sales of its top-selling medicine, Humira, due to larger-than-expected pricing cuts because of new competition in Europe.